Readings from the other desks
The synthetic biology baseline is read through each steward’s lens, then once as a whole. Each lens is a projection of reviewed findings, not a separate argument. The other desks’ own editions of this subject are listed first, as cross-references, not copies.
Contents
- ·Edition home
- ·Executive summary
- 1Synthetic biology is a build capability and a governance test
- 2Key findings
- 3Systems and sectors at baseline
- 4Risks and capability
- 5Design capability outpaces screening and oversight
- 6Readings from the other desks
- 6.1 The other desks’ editions of this subject
- 6.2 Three lenses
- 6.3 Standards, Academy and steward contributions
- 6.4 GCRI reading: the model card
- 6.5 Global Risks Forum reading: editorial essays
- 6.6 Global Risks Alliance reading: 2027 synthetic biology readiness pack
- 6.7 Nexus Standards reading: standards and regulatory watch
- 6.8 Risk Academy reading: literature and evidence review, science and assessments
- 7The 2027 agenda
- 8Systems in depth
- AMethodology
- BData appendix
- CReferences and record
- ·Complete edition, for print
6.1The other desks’ editions of this subject
Federation: each desk writes its own edition for the subjects in its remit. Until a desk releases, its edition shows its frame and the reading this edition printed for it.
| Desk | Edition | State | Identifier |
|---|---|---|---|
| GCRI Systems Evidence | No edition of this subject at this desk in the 2026 Baseline cycle | Not in this cycle | |
| GRF Public Deliberation | Outside this desk’s remit | Not in remit | |
| GRA Capital Readiness | Outside this desk’s remit | Not in remit | |
| Standards Progress | No edition of this subject at this desk in the 2026 Baseline cycle | Not in this cycle | |
| Academy Capability | No edition of this subject at this desk in the 2026 Baseline cycle | Not in this cycle | |
| Index Measurement | Outside this desk’s remit | Not in remit |
6.2Three lenses
One edition, read by each steward. The lens of this site comes first.
GCRI · KEY T
Technical Truth
The evidence supports reading synthetic biology as a build capability, a manufacturing base and a governance test. Build results are strong on single organisms, risk evidence is newer, and the physical footprint is unmeasured. Evidence is strongest for peer-reviewed results and weakest for energy, capacity and screening coverage.
BLD-001 · SEC-005 · GOV-007 · SYS-012
GRF · KEY M
Public Meaning
For most people synthetic biology arrives as a medicine, a food label or a warning about misuse. The baseline asks that public debate separate peer-reviewed results from company statements and plans, and keep oversight of both benefit and risk in view.
CLN-004 · SEC-005 · SEC-006
GRA · KEY F
Capital Meaning
Readiness implications only. Company results are mixed and public programmes are at the planning stage161724. These show where finance-readiness evidence will matter. Nothing here is advice, a rating or an approval.
FIN-011 · GOV-008
NEXUS
Synthesis
Synthetic biology is well described by single results and thinly measured as a system. The 2027 programme should count screening coverage, publish a comparable footprint and test the design and screening gap before the next framework revision.
SYS-012 · Q-01 · Q-02
6.3Standards, Academy and steward contributions
How the Nexus Standards drafts, the Risk Academy and the three stewards feed each quarterly edition for synthetic biology. The standards are a preparatory working draft (2026) and are cited as drafts, never as adopted standards.
| Quarter | Edition | Question | Boundary |
|---|---|---|---|
| Q1 | State and Agenda | What matters this year, and what is the starting position? | observed baseline stays distinct from planned work |
| Q2 | Evidence and Build | What new evidence and capability exist? | a configured capability is not a validated result |
| Q3 | Stress Test and Readiness | What do scenarios and tests show? | simulated loss or performance is not observed impact |
| Q4 | Annual Synthesis and Renewal | What changed in the year, and what renews? | release follows review, not event publicity deadlines |
| Steward or body | Role | Contribution route |
|---|---|---|
| The Global Centre for Risk and Innovation (GCRI Canada) | Lead Institution and Consortium Secretariat; publisher of record; technical truth (key T) | science and practice communities · GCRI gateway |
| The Global Risks Forum (GRF) | leadership, dialogue and the Universe programme; public meaning (key M) | policy, Universe and national adoption · GRF gateway |
| The Global Risks Alliance (GRA) | finance, insurance and development readiness; capital meaning (key F) | finance and insurance · GRA gateway |
| Nexus Standards | preparatory drafts on vocabulary, hazards, indicators and methods | Standards site · working groups HAZ, IND, MTH, FIN, AI |
| Risk Academy | learning pathways tied to the agenda questions | Academy gateway · learning by review |
| Nexus Standards and Academy | technology chapter inputs: GCRI evidence, NXS standards, RA capability | technology editorial board |
Standards drafts used in this edition
- Risk vocabulary NRS-C1 (424 terms) for terms in the glossary
- Hazard atlas NHS-1 1.1.0 (905 hazards in 120 families) for risk objects
- Seven risk classes: global, catastrophic, existential, emerging, planetary, exponential, frontier-tech
Standards calendar to watch
- Founding calls from 20 October 2026; working groups meet from 5 November 2026
- Inaugural Global Standards Council session, 12 January 2027
- Quarterly reviews in March, June, September and December, aligned with each edition
6.4GCRI reading: the model card
GCRI’s reading of this edition is its model card: what the national model is, what it computes and where it stops. It is printed in full in Annex A, with the methods it belongs to. Annex A, methodology
6.5Global Risks Forum reading: editorial essays
Four signed essays by the Reports editorial team set out the positions this edition takes. They are interpretation, labelled as such; the evidence they draw on is in the findings register.
Synthetic biology is a build capability, a manufacturing base and a governance test. The first is advancing fast, the second is thinly measured and the third is unevenly implemented. Keeping them apart avoids both hype and alarm.
EDITORIAL ESSAY · 01
Three stories, one field
A peer-reviewed experiment, a policy proposal and a company announcement carry different weight. This edition labels each, and treats company revenue and guidance as weak evidence.
EDITORIAL ESSAY · 02
Separate results, plans and statements
Feedstock, energy, water, DNA supply and capacity are rarely counted. A published footprint would show whether scale is limited by biology, supply or money.
EDITORIAL ESSAY · 03
The footprint is the blind spot
Screening and dual-use frameworks were written before generative design tools. Evidence shows gaps and fixes, and the work is practice, coverage and shared text across jurisdictions.
EDITORIAL ESSAY · 04
Oversight has to keep pace with design
6.6Global Risks Alliance reading: 2027 synthetic biology readiness pack
The registers that open the 2027 global cycle. At baseline each is initialised from this edition.
| Item | Register | State at baseline | First 2027 entry |
|---|---|---|---|
| E1 | Synthetic biology risk state delta | baseline set by this edition | changes against the baseline |
| E2 | WEFH+B state delta | five global system readings set | indicator updates and freshness |
| E3 | Agenda and Portfolio movement | eight agenda items · 6 proposed objects | admission decisions |
| E4 | Federation delivery register | national chapters in preparation | national chapters |
| E5 | Consortium capability register | national consortia forming | first contributions |
| E6 | Leadership questions and challenges | none yet | first challenge log |
| E7 | Foundry technical state | national environments prepared | first federation cut |
| E8 | Publication candidates | twelve findings carried forward | PUBLISH · HOLD dispositions |
| E9 | Universe readiness | one candidate mission | admission and role spine |
| E10 | Correction register | none | first federation-wide cycle |
Publication dispositions
- Publish
- Hold
- Needs evidence
- Restricted
- Superseded
6.7Nexus Standards reading: standards and regulatory watch
Instruments and published guidance that shape the systems in this edition, by status on the retrieval date. The edition assesses no one’s compliance.
- IN FORCE
- PUBLISHED
- DRAFT
- PUBLISHED · VOLUNTARY
| Instrument | Body | Scope | Status | Relevance |
|---|---|---|---|---|
| Global guidance framework for the life sciences21 | WHO | global | PUBLISHED 2022 | dual-use governance |
| Framework for nucleic acid synthesis screening25 | OSTP | US | PUBLISHED 2024 | screening; status after 2025 order unclear |
| Executive Order 1429226 | US President | US | IN FORCE 2025 | research safety and framework revision |
| Harmonised screening protocol31 | IGSC | industry, global | PUBLISHED · VOLUNTARY | screening practice |
| Screening guidance for synthetic nucleic acids32 | UK Government | UK | PUBLISHED · VOLUNTARY | screening practice |
| ISO 20688-2 on gene synthesis36 | ISO | global | PUBLISHED · VOLUNTARY | production requirements |
| Biotech Act proposal2228 | European Commission | EU | DRAFT | health biotechnology and biodefence |
| CBD decisions 15/31 and 16/2120 | CBD parties | global | PUBLISHED | horizon scanning and action plan |
| Cartagena Protocol35 | CBD parties | global | IN FORCE | living modified organisms |
| Biological Weapons Convention34 | States Parties | global | IN FORCE | prohibition |
Changed since 2024
6.8Risk Academy reading: literature and evidence review, science and assessments
The review behind this edition covers synthetic biology assessments, peer-reviewed science and the institutional reports that bind its findings. Systematic reviews for each agenda item begin in 2027.
Review protocol
- Question
- What does the published evidence establish about synthetic biology and bioengineering as infrastructure and its couplings?
- Sources searched
- peer-reviewed journals; regulator and agency pages; policy papers; company filings
- Window
- releases available at evidence close, 30 September 2026
- Selection
- sources that bind or contextualise a finding in this edition
- Next step
- systematic reviews for agenda items 01 to 05 in 2027
| Reference | Type | Year | Role | Used for |
|---|---|---|---|---|
| Robertson et al.1 | journal article | 2025 | supports | recoded genome |
| Fredens et al.3 | journal article | 2019 | supports | recoded genome |
| Sc2.0 consortium paper4 | journal article | 2023 | supports | synthetic yeast |
| Gibson et al.5 | journal article | 2010 | context | first synthetic cell |
| Nielsen et al.6 | journal article | 2016 | supports | circuit design |
| Watson et al.7 | journal article | 2023 | supports | protein design |
| Frangoul et al.8 | journal article | 2024 | supports | cell therapy |
| Musunuru et al.10 | journal article | 2025 | context | patient-specific therapy |
| Reference | Issuer | Year | Role | Used for |
|---|---|---|---|---|
| Kyrou et al.11 | journal article | 2018 | context | gene drive |
| Mirror life policy forum12 | journal article | 2024 | context | risk discussion |
| Screening study13 | journal article | 2025 | supports | screening gaps |
| Jinek et al.38 | journal article | 2012 | framework | CRISPR programmable cutting |
| Gibson et al.39 | journal article | 2009 | framework | DNA assembly |
| Ro et al.40 | journal article | 2006 | framework | engineered yeast production |
| Elowitz and Leibler41 | journal article | 2000 | framework | synthetic oscillator |
| Gardner, Cantor and Collins42 | journal article | 2000 | framework | genetic toggle switch |
| Richardson et al.43 | journal article | 2017 | framework | synthetic yeast design |
| Reference | Issuer | Year | Role | Used for |
|---|---|---|---|---|
| US commission report, CRS note14 | Congressional Research Service | 2025 | supports | recommendations |
| OECD anticipatory governance18 | OECD | 2026 | supports | governance |
| OECD technology assessment19 | OECD | 2025 | supports | convergence and risks |
| CBD synthetic biology page20 | CBD secretariat | 2026 | supports | decisions |
| WHO framework21 | WHO | 2022 | supports | dual-use guidance |
| Biodefense report33 | National Academies | 2018 | context | biodefence background |
| EU proposal summary22 | law firm summary | 2025 | context | proposal content |
| Reference | Issuer | Year | Role | Used for |
|---|---|---|---|---|
| FAS commentary15 | Federation of American Scientists | 2025 | context | bioeconomy figures |
| Twist Bioscience filing16 | company | 2026 | context | weak signal |
| Ginkgo Bioworks filing17 | company | 2026 | context | weak signal |
| BioMADE page23 | institute | 2020 | context | infrastructure |
| Programme page24 | US manufacturing programme | 2024 | supports | planning awards |
| Bio Revolution report37 | McKinsey | 2020 | context | economy |
Where the evidence agrees
Notes
Numbers are the edition’s reference numbers, so a note reads the same in every chapter. The full list, with every source and its licence, is in Annex C. Annex C, references
- 16Twist Bioscience Corporation (ed.), Form 8-K exhibit 99.1, results for the fiscal third quarter ended 30 June 2026 (company filing; revenue USD 118.4 million; nine months USD 332.8 million; fiscal 2026 guidance USD 456 to 457 million; company statements and guidance are weak evidence). US Securities and Exchange Commission, Washington. Observation year 2026. Accessed 2026-11-03.back
- 17Ginkgo Bioworks Holdings, Inc. (ed.), Form 8-K exhibit 99.1, fourth quarter and full year 2025 results (company filing of 26 February 2026; revenue USD 170.155 million against USD 227.043 million; net loss USD 312.763 million; company statements are weak evidence). US Securities and Exchange Commission, Washington. Observation year 2025. Accessed 2026-11-03.back
- 24US Manufacturing Program (ed.), Bioindustrial (programme topic page; Distributed Bioindustrial Manufacturing Program awards announced 10 July to 13 September 2024; 25 awards; USD 42 million cumulative). Manufacturing USA, Gaithersburg. Observation year 2024. Accessed 2026-11-03.back
- 21World Health Organization (ed.), Global guidance framework for the responsible use of the life sciences: mitigating biorisks and governing dual-use research (publication page, 13 September 2022). WHO, Geneva. Observation year 2022. Accessed 2026-11-03.back
- 25UNVERIFIED, not opened: Office of Science and Technology Policy (ed.), Framework for Nucleic Acid Synthesis Screening, April 2024, taken from search-result summaries; a fetch of the page was refused by the fetch tool. OSTP, Washington. Observation year 2024. Accessed 2026-11-03.back
- 26UNVERIFIED, not opened: Executive Order 14292, Improving the Safety and Security of Biological Research, 5 May 2025 (90 days to revise or replace the framework), taken from search-result summaries; a fetch of an explainer page was refused by the fetch tool. The White House, Washington. Observation year 2025. Accessed 2026-11-03.back
- 31UNVERIFIED, not opened: International Gene Synthesis Consortium (ed.), Harmonized Screening Protocol, cited from memory. IGSC. Observation year 2024. Accessed 2026-11-03.back
- 32UNVERIFIED, not opened: UK Government (ed.), screening guidance on synthetic nucleic acids, 2024, cited from memory. Department for Science, Innovation and Technology, London. Observation year 2024. Accessed 2026-11-03.back
- 36UNVERIFIED, not opened: International Organization for Standardization (ed.), ISO 20688-2, requirements for the production and quality control of synthesised gene fragments, genes and genome-scale constructs, cited from memory. ISO, Geneva. Observation year 2024. Accessed 2026-11-03.back
- 22Baker McKenzie (ed.), EU Biotech Act unveiled: Commission proposal to turn Europe into a biotech powerhouse (law firm summary, 19 December 2025; proposal of 16 December 2025; health focus; investment pilot with the European Investment Bank Group; 12-month certificate extension; biodefence measures; second act expected in Q3 2026). Secondary source, not the Commission text. Observation year 2025. Accessed 2026-11-03.back
- 28UNVERIFIED, not opened: European Commission (ed.), Proposal for a Biotech Act, COM(2025) 1022, 16 December 2025, taken from law firm and regulator summaries; the Commission page was not retrieved. European Commission, Brussels. Observation year 2025. Accessed 2026-11-03.back
- 20Secretariat of the Convention on Biological Diversity (ed.), Synthetic biology (programme page; decisions X/13 to 16/21; AHTEG; horizon scanning; thematic action plan). CBD Secretariat, Montreal. Observation year 2026. Accessed 2026-11-03.back
- 35UNVERIFIED, not opened: Cartagena Protocol on Biosafety to the Convention on Biological Diversity, 2000, cited from memory. CBD Secretariat, Montreal. Observation year 2000. Accessed 2026-11-03.back
- 34UNVERIFIED, not opened: Convention on the Prohibition of the Development, Production and Stockpiling of Bacteriological (Biological) and Toxin Weapons and on their Destruction, 1972, cited from memory. United Nations, Geneva. Observation year 1972. Accessed 2026-11-03.back
- 18OECD (ed.), Anticipatory governance for responsible innovation in synthetic biology, OECD Science, Technology and Industry Policy Papers No. 193, 21 May 2026 (record read via a bibliographic database; abstract only). OECD Publishing, Paris. Observation year 2026. Accessed 2026-11-03.back
- 29UNVERIFIED, not opened: European Parliament (ed.), Legislative train entry for the European Biotech Act II (second act expected in the third quarter of 2026), taken from a search-result summary; the page returned no content. European Parliament, Brussels. Observation year 2026. Accessed 2026-11-03.back
- 27UNVERIFIED, not opened: Congressional Research Service (ed.), report on artificial intelligence and biosecurity risks (reported in July 2026 as unable to determine whether the 2024 framework or the 2025 policy had been revised), taken from a trade news summary. Library of Congress, Washington. Observation year 2026. Accessed 2026-11-03.back
- 1Robertson, W.E. et al., Escherichia coli with a 57-codon genetic code, Science 390 (6771), eady4368, published 23 October 2025 (record read via PubMed, PMID 40743368; the record gives a 4 megabase synthetic genome and six replaced sense codons). American Association for the Advancement of Science, Washington. Observation year 2025. Accessed 2026-11-03.back
- 3Fredens, J. et al., Total synthesis of Escherichia coli with a recoded genome, Nature 569 (7757), 514 to 518, 2019 (record read via Europe PMC: 18,214 codons recoded; 61-codon genome). Springer Nature, London. Observation year 2019. Accessed 2026-11-03.back
- 4Debugging and consolidating multiple synthetic chromosomes reveals combinatorial genetic interactions, Cell 186 (24), 5220 to 5236, 2023 (record read via Europe PMC: 6.5 synthetic chromosomes in one strain; over half of the Sc2.0 genome). Cell Press, Cambridge, Massachusetts. Observation year 2023. Accessed 2026-11-03.back
- 5Gibson, D.G. et al., Creation of a bacterial cell controlled by a chemically synthesised genome, Science 329 (5987), 52 to 56, 2010 (record read via Europe PMC: 1.08 million base pair genome). American Association for the Advancement of Science, Washington. Observation year 2010. Accessed 2026-11-03.back
- 6Nielsen, A.A.K. et al., Genetic circuit design automation, Science 352 (6281), 2016 (record read via Europe PMC: 60 circuits; 45 correct in all output states; 92% of output states as predicted). American Association for the Advancement of Science, Washington. Observation year 2016. Accessed 2026-11-03.back
- 7Watson, J.L. et al., De novo design of protein structure and function with RFdiffusion, Nature 620, 1089 to 1100, 2023 (record read via Europe PMC). Springer Nature, London. Observation year 2023. Accessed 2026-11-03.back
- 8Frangoul, H. et al., Exagamglogene autotemcel for severe sickle cell disease, New England Journal of Medicine 390 (18), 1649 to 1662, 2024 (record read via Europe PMC: 44 treated; 29 of 30 evaluable free of severe crises for 12 months; median follow-up 19.3 months). Massachusetts Medical Society, Waltham. Observation year 2024. Accessed 2026-11-03.back
- 10Musunuru, K. et al., Patient-specific in vivo gene editing to treat a rare genetic disease, New England Journal of Medicine 392 (22), 2235 to 2243, 2025 (record read via Europe PMC: one infant; two infusions at about 7 and 8 months). Massachusetts Medical Society, Waltham. Observation year 2025. Accessed 2026-11-03.back
- 11Kyrou, K. et al., A CRISPR-Cas9 gene drive targeting doublesex causes complete population suppression in caged Anopheles gambiae mosquitoes, Nature Biotechnology 36, 1062 to 1066, 2018 (record read via Europe PMC; laboratory cages only). Springer Nature, London. Observation year 2018. Accessed 2026-11-03.back
- 12Confronting risks of mirror life, Science 386, 1351 to 1353, 2024 (record read via Europe PMC; the record gives only a one-line abstract calling for broad discussion). American Association for the Advancement of Science, Washington. Observation year 2024. Accessed 2026-11-03.back
- 13Strengthening nucleic acid biosecurity screening against generative protein design tools, Science 390 (6768), 82 to 87, 2025 (record read via Europe PMC; abstract only; no method detail used). American Association for the Advancement of Science, Washington. Observation year 2025. Accessed 2026-11-03.back
- 38UNVERIFIED, not opened: Jinek, M. et al., A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity, Science 337, 816 to 821, 2012, cited from memory. Observation year 2012. Accessed 2026-11-03.back
- 39UNVERIFIED, not opened: Gibson, D.G. et al., Enzymatic assembly of DNA molecules up to several hundred kilobases, Nature Methods 6, 343 to 345, 2009, cited from memory. Observation year 2009. Accessed 2026-11-03.back
- 40UNVERIFIED, not opened: Ro, D.-K. et al., Production of the antimalarial drug precursor artemisinic acid in engineered yeast, Nature 440, 940 to 943, 2006, cited from memory. Observation year 2006. Accessed 2026-11-03.back
- 41UNVERIFIED, not opened: Elowitz, M.B. and Leibler, S., A synthetic oscillatory network of transcriptional regulators, Nature 403, 335 to 338, 2000, cited from memory. Observation year 2000. Accessed 2026-11-03.back
- 42UNVERIFIED, not opened: Gardner, T.S., Cantor, C.R. and Collins, J.J., Construction of a genetic toggle switch in Escherichia coli, Nature 403, 339 to 342, 2000, cited from memory. Observation year 2000. Accessed 2026-11-03.back
- 43UNVERIFIED, not opened: Richardson, S.M. et al., Design of a synthetic yeast genome, Science 355, 1040 to 1044, 2017, cited from memory. Observation year 2017. Accessed 2026-11-03.back
- 14Congressional Research Service (ed.), National Security Commission on Emerging Biotechnology: Final Report and Options for Congress, CRS Insight IN12546, 17 April 2025 (report of 8 April 2025; 49 recommendations; at least USD 15 billion over five years; National Biotechnology Coordination Office). Library of Congress, Washington. Observation year 2025. Accessed 2026-11-03.back
- 19OECD (ed.), Synthetic biology, AI and automation: a forward-looking technology assessment, OECD Science, Technology and Industry Policy Papers No. 187, 4 December 2025 (record read via a bibliographic database; abstract only). OECD Publishing, Paris. Observation year 2025. Accessed 2026-11-03.back
- 33UNVERIFIED, not opened: National Academies of Sciences, Engineering, and Medicine (eds.), Biodefense in the Age of Synthetic Biology, 2018, cited from memory; a fetch returned an unrelated page. National Academies Press, Washington. Observation year 2018. Accessed 2026-11-03.back
- 15Federation of American Scientists (ed.), Translating Vision into Action: FAS commentary on the NSCEB final report (commentary page; six pillars; cites over USD 210 billion of US GDP and over 640,000 jobs for the bioeconomy; secondary and advocacy-leaning source). Federation of American Scientists, Washington. Observation year 2025. Accessed 2026-11-03.back
- 23BioMADE (ed.), DoD approves USD 87 million for newest bioindustrial manufacturing innovation institute (news page; seven years; the page shows Oct 20 and a 2023 footer, the press release is dated 2020 in search listings). BioMADE, Saint Paul. Observation year 2020. Accessed 2026-11-03.back
- 37UNVERIFIED, not opened: McKinsey Global Institute (ed.), The Bio Revolution: Innovations transforming economies, societies, and our lives, May 2020, cited from memory; the fetch returned a service error and no figure is used. McKinsey and Company, New York. Observation year 2020. Accessed 2026-11-03.back